Caplin Point Laboratories Limited share price

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Smallcap 250NSE: CAPLIPOINTISIN INE475E01026

16 Oct 2026, 3:30 PM IST₹2,301.30▼ 0.50 (0.02%)

Market Cap₹ 17,493 Cr.
Current Price₹ 2,301.30
High / Low₹ 2,990 / 1,500
Stock P/E26.4
Book Value₹ 462
Dividend Yield0.35 %
ROCE22.0 %
ROE19.90 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 87.28
Price / Book4.98
OPM32.0 %
Debt / Equity0.00
Sales growth (5Y)15.6 %
Profit growth (5Y)20.9 %
Promoter holding73.4 %
EV / EBITDA20.9
Beta0.42
All-time high₹ 2,990

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
CAPLIPOINT	-10.91%	-13.86%	+30.39%	+25.20%	+14.19%	+28.15%	+20.32%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Caplin Point Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹17,493 crore.
It trades at 26.4 times its last 12 months' earnings and 5.0 times book value.
Revenue grew 15.6% a year over the last 5 years, profit 20.9% a year.
Return on equity was 19.9% and return on capital employed 22.0% in the latest year.
Debt was 0.00 times shareholders' equity.
The share price is 23.0% below its 52-week high and up 14.2% over one year.
Promoters and insiders hold about 73.4%; institutions about 5.7%.

Pros

Strong return on equity: 20.8% on average over the last 3 years.
Company is almost debt-free (debt is 0.00 times equity).
Sales have grown 15.6% a year over the last 5 years.
Profit has grown 20.9% a year over the last 5 years.
Latest quarter (Jun 2026): sales up 20% and profit up 19% from a year ago.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Caplin Point Laboratories Limited

Employees: 4,199
Head office: Chennai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Smallcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Caplin Point Laboratories	2,301.30	26.4	17,493	0.35	179	18.79	610	19.63	22.0	19.9	4.98	32.0	0.00	73.44	2,187	15.6
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 61 Co.	1,909.45	34.1	11,199	0.17	680	16.54	6,020	18.81	16.4	13.2	3.86	15.1	0.21	55.20	20,499	11.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	395	410	436	453	459	483	493	502	510	534	543	600	610
YOY Sales Growth %	14.15%	14.21%	17.05%	16.43%	16.10%	17.81%	13.19%	10.86%	11.17%	10.54%	10.10%	19.45%	19.63%
	269	273	293	308	307	318	331	334	332	345	353	396	397
Material Cost %	45%	40%	44%	42%	40%	39%	40%	40%	38%	39%	40%	41%	40%
Employee Cost %	9%	9%	8%	8%	9%	9%	9%	9%	8%	9%	9%	9%	9%
Other Expenses %	14%	18%	15%	18%	18%	18%	18%	17%	18%	16%	16%	16%	16%
Operating Profit	127	137	142	145	152	165	162	168	178	189	190	204	213
OPM %	32%	34%	33%	32%	33%	34%	33%	33%	35%	35%	35%	34%	35%
	12	20	17	17	19	21	31	26	23	30	34	28	34
Exceptional items				0
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	11	12	14	16	16	17	16	17	16	18	19	19	22
Profit before tax	127	146	145	146	154	169	177	177	184	201	204	213	225
	18%	20%	18%	17%	19%	22%	21%	18%	18%	20%	19%	19%	20%
Current tax	24	31	26	21	29	32	34	29	33	37	36	41	46
Deferred tax	-2	-1	-0	4	0	5	3	2	1	4	2	-0	-0
	104	116	120	121	125	131	140	145	151	160	166	173	179
Profit from associates		0	0		0	-0	-0	0	0	0	-0		-0
Minority share	1	1	3	-0	1	0	1	3	-2	6	2	3	2
Profit to shareholders	103	115	117	122	124	131	139	141	153	154	164	170	177
YOY Profit Growth %	20.76%	26.20%	23.04%	19.75%	19.85%	12.63%	16.89%	19.84%	20.69%	22.49%	18.41%	19.00%	18.79%
EPS in Rs	13.62	15.13	15.44	16.01	16.32	17.22	18.28	18.75	20.10	20.32	21.56	22.38	23.27
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	174	179	133	139	186	208	185	174	183	175	189	191	203
YOY Sales Growth %	49.21%	30.87%	1.71%	-3.66%	6.90%	16.02%	39.45%	24.56%	-1.65%	-15.75%	2.15%	10.22%	11.16%
	97	90	70	82	104	110	108	99	96	99	98	108	109
Material Cost %	37%	31%	31%	31%	33%	30%	33%	32%	32%	33%	30%	29%	29%
Employee Cost %	6%	5%	7%	7%	6%	6%	7%	8%	5%	7%	7%	7%	7%
Other Expenses %	14%	14%	14%	20%	18%	17%	18%	17%	15%	17%	14%	20%	18%
Operating Profit	77	89	63	58	81	98	77	75	87	76	92	84	94
OPM %	44%	50%	48%	41%	44%	47%	42%	43%	47%	43%	48%	44%	47%
Other Income	27	24	18	36	22	43	29	41	32	59	32	61	63
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	7	7	7	7	6	6	6	6	6	6	6	7	7
Profit before tax	97	107	74	87	97	135	100	110	112	129	117	138	151
	22%	23%	26%	20%	25%	21%	25%	21%	24%	20%	25%	20%	20%
Current tax	22	27	20	17	25	29	26	24	27	27	29	26	29
Deferred tax	-1	-2	-1	-0	-0	-0	-0	0	-0	-0	0	2	1
	76	82	55	70	73	106	75	87	86	103	87	110	120
YOY Profit Growth %	20.60%	42.75%	-6.29%	28.62%	-4.89%	28.80%	34.73%	23.78%	18.40%	-2.98%	16.83%	26.59%	40.16%
EPS in Rs	10.04	10.82	7.30	9.20	9.55	13.92	9.83	11.37	11.30	13.50	11.49	15.89	15.84
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	540	540	863	1,061	1,269	1,467	1,694	1,937	2,187	2,287
YOY Sales Growth %			59.90%	22.95%	19.61%	15.54%	15.50%	14.37%	12.89%
	345	345	603	733	875	1,026	1,143	1,291	1,426	1,491
Material Cost %	44%	44%	48%	44%	44%	45%	43%	40%	40%	40%
Employee Cost %	7%	7%	8%	10%	9%	9%	8%	9%	9%	9%
Other Expenses %	13%	13%	14%	15%	16%	15%	16%	18%	17%	16%
Operating Profit	195	195	260	329	395	441	551	647	761	797
OPM %	36%	36%	30%	31%	31%	30%	33%	33%	35%	35%
	13	13	41	24	39	56	67	96	116	126
Exceptional items						0	0		0
Interest	0	0	0	2	1	1	1	1	1	1
Depreciation	19	19	32	37	47	45	53	66	73	78
Profit before tax	188	188	269	314	386	451	564	677	803	844
	23%	23%	20%	20%	20%	16%	18%	20%	19%	20%
Current tax	41	41	62	71	84	82	102	125	146
Deferred tax	3	3	-7	-9	-7	-8	1	10	7
	145	145	215	251	308	377	461	541	650	678
Profit from associates								-0		-0
Minority share	-0	-0	0	9		1	4	5	8	13
Profit to shareholders	145	145	215	242		376	457	563	641	665
YOY Profit Growth %			48.71%	16.90%	22.67%	22.22%	22.40%	17.27%	20.08%
EPS in Rs	19.26	19.26	28.42	32.03	39.61	49.62	60.19	70.57	84.36	87.53
Dividend Payout %						8%	7%	7%	7%

Compounded Sales Growth

5 Years:: 16%
3 Years:: 14%
TTM:: 15%

Compounded Profit Growth

5 Years:: 21%
3 Years:: 20%
TTM:: 20%

Stock Price CAGR

5 Years:: 20%
3 Years:: 28%
1 Year:: 14%

Return on Equity

4 Years:: 21%
Last Year:: 20%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	427	427	537	528	483	528	529	625	752	738	759
YOY Sales Growth %			25.86%	-1.69%	-8.55%	9.40%	0.10%	18.25%	20.37%	-1.87%
	285	285	349	321	269	308	309	338	420	401	413
Material Cost %	42%	42%	44%	45%	40%	39%	37%	33%	32%	31%	30%
Employee Cost %	9%	9%	8%	5%	6%	6%	7%	6%	7%	6%	7%
Other Expenses %	15%	15%	13%	11%	10%	14%	14%	15%	17%	17%	17%
Operating Profit	142	142	188	207	214	220	220	287	332	338	346
OPM %	33%	33%	35%	39%	44%	42%	42%	46%	44%	46%	46%
Other Income	23	23	35	66	19	57	99	106	135	195	215
Interest	0	0	0	0	0	0	0	0	0	0	0
Depreciation	19	19	21	20	22	26	26	27	25	25	26
Profit before tax	146	146	203	253	210	250	293	366	442	508	534
	30%	30%	27%	22%	26%	25%	20%	22%	23%	22%	21%
Current tax	41	41	54	56	55	62	67	86	103	109
Deferred tax	3	3	0	-0	-1	1	-8	-4	-1	1
	102	102	148	198	156	188	234	284	339	397	420
YOY Profit Growth %			44.82%	33.39%	-20.95%	20.25%	24.69%	21.11%	19.66%	16.82%
EPS in Rs	13.64	13.64	19.60	26.13	20.65	24.82	30.89	37.36	44.67	52.17	56.72
Dividend Payout %							13%	12%	11%	12%

Compounded Sales Growth

5 Years:: 9%
3 Years:: 12%
TTM:: 1%

Compounded Profit Growth

5 Years:: 20%
3 Years:: 19%
TTM:: 19%

Stock Price CAGR

5 Years:: 20%
3 Years:: 28%
1 Year:: 14%

Return on Equity

4 Years:: 21%
Last Year:: 20%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15	15	15	15
Reserves	1,865	2,301	2,835	3,571
	5	2	5	5
Short term borrowings	3	0	1	1
	305	380	355	454
Trade payables	153	230	218	296
Minority interest	27	31	36	44
Current liabilities	268	331	306	386
Total Liabilities	2,191	2,698	3,211	4,045
	489	557	674	760
Gross block	682	796	974	1,129
Accumulated depreciation	193	240	300	369
Goodwill & intangibles	11	13	18	54
CWIP	220	117	139	209
	1,482	2,025	2,398	3,077
Inventories	288	363	336	429
Trade receivables	394	543	632	826
Cash & equivalents	484	546	199	606
Current assets	1,552	1,893	2,134	2,586
Total Assets	2,191	2,698	3,211	4,045

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	271	318	432	523
Profit for the year	376	457	536	641
Working capital changes	-104	-139	-122	-109
Direct taxes paid	-88	-109	-128	-145
	-218	-320	-335	-582
Fixed assets purchased	-193	-146	-192	-248
Investments purchased	-141	-122
Investments sold	92	0
	-28	-38	-38	-46
Interest paid	-1	-1	-1	-1
Dividends paid	-30	-34	-38	-46
Net Cash Flow	26	-40	59	-106
Free Cash Flow	78	173	241	275

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	20.0%	21.8%	20.8%	19.9%
ROCE	—	23.5%	23.9%	23.3%	22.0%
Operating margin	—	27.4%	29.7%	30.6%	32.0%
Net margin	—	25.9%	27.2%	27.9%	29.5%
Debt / equity	—	0.00	0.00	0.00	0.00
Current ratio	—	5.79	5.72	6.97	6.70
Debtor days	—	99	118	120	139
Inventory days	—	157	182	158	179
Days payable	—	83	115	102	124
Cash conversion cycle	—	173	185	176	194
Working capital days	—	322	339	347	370

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 70.57%
FIIs 5.75%
DIIs 2.49%
Public 21.18%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	70.63%	70.62%	70.62%	70.56%	70.56%	70.56%	70.56%	70.56%	70.57%	70.57%	70.57%	70.57%
	3.09%	2.85%	3.34%	3.37%	3.70%	4.86%	5.73%	6.17%	6.51%	6.59%	6.15%	5.75%
Foreign portfolio investors (Cat. I)	2.82%	2.58%	3.13%	2.99%	3.30%	4.40%	5.14%	5.81%	6.17%	6.28%	5.79%	5.24%
Foreign portfolio investors (Cat. II)	0.26%	0.25%	0.19%	0.37%	0.39%	0.44%	0.56%	0.32%	0.31%	0.27%	0.36%	0.52%
	0.20%	0.43%	1.09%	1.49%	1.84%	2.11%	2.01%	2.22%	2.10%	2.05%	2.14%	2.49%
Mutual funds	0.05%	0.41%	1.06%	1.32%	1.62%	1.86%	1.74%	1.93%	1.79%	1.97%	2.02%	2.03%
Insurance companies	0.13%			0.08%	0.15%	0.14%	0.20%	0.22%	0.23%	0.01%	0.01%	0.03%
Banks	0.01%
Alternative investment funds	0.02%	0.02%	0.02%	0.09%	0.06%	0.11%	0.06%	0.07%	0.08%	0.07%	0.11%	0.43%
	26.08%	26.10%	24.95%	24.57%	23.90%	22.47%	21.70%	21.05%	20.82%	20.79%	21.14%	21.18%
Retail (up to ₹2 lakh)	12.70%	12.43%	12.34%	12.48%	12.74%	11.85%	11.68%	11.66%	11.63%	11.81%	12.17%	12.14%
HNIs (above ₹2 lakh)	5.61%	5.93%	5.25%	5.02%	4.38%	3.92%	3.43%	2.66%	2.57%	2.33%	2.29%	2.48%
NRIs	1.31%	1.35%	1.37%	1.34%	1.40%	1.41%	1.40%	1.39%	1.33%	1.35%	1.36%	1.38%
Bodies corporate	1.77%	1.63%	1.41%	1.16%	0.99%	0.91%	0.85%	0.95%	0.98%	0.96%	1.53%	1.56%
IEPF	2.65%	2.73%	2.72%	2.72%	2.71%	2.76%	2.74%	2.73%	2.71%	3.11%	3.04%	2.87%
No. of Shareholders	78,068	79,438	81,409	80,411	96,123	92,702	96,387	94,169	93,753	93,705	93,896	94,385

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Caplin Point Laboratories

Holder (above 1%)	Stake
UTI Multi Cap FundMutual fund	1.81%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 2.03% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 18 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Caplin Point Laboratories Limited

What is the share price of Caplin Point Laboratories Limited today?

Caplin Point Laboratories Limited (CAPLIPOINT) last traded at ₹2,301.30 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Caplin Point Laboratories Limited?

About ₹17,493 crore at the latest price.

What is the P/E ratio of Caplin Point Laboratories Limited?

About 26.4 times its earnings over the last 12 months.

Is Caplin Point Laboratories Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Caplin Point Laboratories Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Caplin Point Laboratories Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Caplin Point Laboratories Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Caplin Point Laboratories

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Caplin Point Laboratories Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next